COVID-19 Pandemic and Clinical Oncology Concerns
10.15520/jmbas.v8i6.231
Resumo
Purpose: The purpose of this review article is concerns on that
cancer patients are regarded as a highly vulnerable group in the current
Coronavirus Disease 2019 (COVID-19) pandemic.
Methods: A literature search was performed using the PubMed
database and the Cochrane library. Search terms included ”novel coronavirus”
or “2019-nCoV” and “clinical oncology”. Authors re- viewed
cancer registry information, status, and treatments.
Results: COVID-19-infected cancer patients were included and the last
anti-tumor treatment was within 14 days, it significantly increased the
risk of developing severe events. Lung cancer was the most frequent
cancer type. The common chest computed tomography (CT) findings
were ground- glass opacity and patchy consolidation. A total of patients
had severe events and the mortality rate was high. Furthermore, patchy
consolidation on CT on admission was associated with a higher risk of
developing severe events.
Conclusions: Cancer patients show deteriorating conditions and poor
outcomes from the COVID-19 infection. It is recommended that cancer
patients receiving anti-tumor treatments should have vigorous screening
for COVID-19 infection and should avoid treatments causing immuno
suppression or have their dosages decreased in case of COVID-19
infection.
How to Cite
Hyunjo Kim, Jae-Hoon Song (2020). COVID-19 Pandemic and Clinical Oncology Concerns. Journal of Medical Biomedical and Applied Sciences , v. 8 n. 6 (2020) , 442-454 . https://doi.org/10.15520/jmbas.v8i6.231